VIP regimen: Difference between revisions
Created page with "__NOTOC__ {{SI}} {{CMG}}; {{AE}} {{AV}} {{SK}}Etoposide-Ifosfamide-Cisplatin Regimen; VePesid-Ifosfamide-Platinol Regimen; VIP; VIP Regimen; VP16-Ifosfamide-Platinol Regimen..." |
No edit summary |
||
| Line 6: | Line 6: | ||
==Overview== | ==Overview== | ||
{{PAGENAME}} refers to a regimen consisting of [[etoposide|etoposide (vepesid)]], [[ifosfamide]] and [[cisplatin|cisplatin (platinol)]] used for the treatment of advanced-stage [[germ cell | {{PAGENAME}} refers to a regimen consisting of [[etoposide|etoposide (vepesid)]], [[ifosfamide]] and [[cisplatin|cisplatin (platinol)]] used for the treatment of advanced-stage [[germ cell tumour|germ cell gonadal cancers]]<ref name="pmid9552027">{{cite journal| author=Nichols CR, Catalano PJ, Crawford ED, Vogelzang NJ, Einhorn LH, Loehrer PJ| title=Randomized comparison of cisplatin and etoposide and either bleomycin or ifosfamide in treatment of advanced disseminated germ cell tumors: an Eastern Cooperative Oncology Group, Southwest Oncology Group, and Cancer and Leukemia Group B Study. | journal=J Clin Oncol | year= 1998 | volume= 16 | issue= 4 | pages= 1287-93 | pmid=9552027 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=9552027 }} </ref> and Thymoma.<ref name="pmid11391579">{{cite journal| author=Loehrer PJ, Jiroutek M, Aisner S, Aisner J, Green M, Thomas CR et al.| title=Combined etoposide, ifosfamide, and cisplatin in the treatment of patients with advanced thymoma and thymic carcinoma: an intergroup trial. | journal=Cancer | year= 2001 | volume= 91 | issue= 11 | pages= 2010-5 | pmid=11391579 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=11391579 }} </ref> | ||
==Regimen== | ==Regimen== | ||
{{chemo|V|VePesid (etoposide)}} | {{chemo|V|VePesid (etoposide)}} | ||
| Line 17: | Line 16: | ||
==Indications== | ==Indications== | ||
*[[germ cell | *[[germ cell tumour|Germ cell gonadal cancers]]<ref name="pmid9552027">{{cite journal| author=Nichols CR, Catalano PJ, Crawford ED, Vogelzang NJ, Einhorn LH, Loehrer PJ| title=Randomized comparison of cisplatin and etoposide and either bleomycin or ifosfamide in treatment of advanced disseminated germ cell tumors: an Eastern Cooperative Oncology Group, Southwest Oncology Group, and Cancer and Leukemia Group B Study. | journal=J Clin Oncol | year= 1998 | volume= 16 | issue= 4 | pages= 1287-93 | pmid=9552027 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=9552027 }} </ref> and Thymoma.<ref name="pmid11391579">{{cite journal| author=Loehrer PJ, Jiroutek M, Aisner S, Aisner J, Green M, Thomas CR et al.| title=Combined etoposide, ifosfamide, and cisplatin in the treatment of patients with advanced thymoma and thymic carcinoma: an intergroup trial. | journal=Cancer | year= 2001 | volume= 91 | issue= 11 | pages= 2010-5 | pmid=11391579 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=11391579 }} </ref> | ||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
[[Category:Chemotherapy regimens]] | [[Category:Chemotherapy regimens]] | ||
Revision as of 13:36, 30 March 2015
|
WikiDoc Resources for VIP regimen |
|
Articles |
|---|
|
Most recent articles on VIP regimen Most cited articles on VIP regimen |
|
Media |
|
Powerpoint slides on VIP regimen |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on VIP regimen at Clinical Trials.gov Clinical Trials on VIP regimen at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on VIP regimen
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on VIP regimen Discussion groups on VIP regimen Patient Handouts on VIP regimen Directions to Hospitals Treating VIP regimen Risk calculators and risk factors for VIP regimen
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for VIP regimen |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aparna Vuppala, M.B.B.S. [2]
Synonyms and keywords:Etoposide-Ifosfamide-Cisplatin Regimen; VePesid-Ifosfamide-Platinol Regimen; VIP; VIP Regimen; VP16-Ifosfamide-Platinol Regimen
Overview
VIP regimen refers to a regimen consisting of etoposide (vepesid), ifosfamide and cisplatin (platinol) used for the treatment of advanced-stage germ cell gonadal cancers[1] and Thymoma.[2]
Regimen
VVePesid (etoposide)
IIfosfamide
PPlatinol (cisplatin)
Indications
- Germ cell gonadal cancers[1] and Thymoma.[2]
References
- ↑ 1.0 1.1 Nichols CR, Catalano PJ, Crawford ED, Vogelzang NJ, Einhorn LH, Loehrer PJ (1998). "Randomized comparison of cisplatin and etoposide and either bleomycin or ifosfamide in treatment of advanced disseminated germ cell tumors: an Eastern Cooperative Oncology Group, Southwest Oncology Group, and Cancer and Leukemia Group B Study". J Clin Oncol. 16 (4): 1287–93. PMID 9552027.
- ↑ 2.0 2.1 Loehrer PJ, Jiroutek M, Aisner S, Aisner J, Green M, Thomas CR; et al. (2001). "Combined etoposide, ifosfamide, and cisplatin in the treatment of patients with advanced thymoma and thymic carcinoma: an intergroup trial". Cancer. 91 (11): 2010–5. PMID 11391579.